Cadrenal Therapeutics (CVKD) Share-based Compensation (2022 - 2026)

Cadrenal Therapeutics has reported Share-based Compensation for 5 years, with the latest figure at $2.1 million in Q1 2026.

• Quarterly Share-based Compensation rose 282.68% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (up 16.34% YoY) and the FY2025 annual result came in at $2.3 million, up 62.08% from the prior year.
• Share-based Compensation climbed to $2.1 million in Q1 2026 per CVKD's latest filing, from $458478.0 in the prior quarter.
• Over five years, Share-based Compensation peaked at $2.8 million in Q3 2025 and troughed at $98933.0 in Q3 2023.
• A 5-year average of $637216.9 and a median of $367880.5 in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2025: Share-based Compensation sank 77.05% in 2023, then jumped 1331.62% in 2025.
• Over 5 years, Share-based Compensation stood at $449365.0 in 2022, then tumbled by 77.05% to $103115.0 in 2023, then surged by 741.4% to $867605.0 in 2024, then plunged by 47.16% to $458478.0 in 2025, then surged by 358.04% to $2.1 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.1 million, $458478.0, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.